Medigene's drug Veregen® receives market authorization notification in Taiwan

Martinsried/Munich, 4 June, 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announces that its drug Veregen® has obtained market authorization notification in Taiwan. Market launch of the ointment by Medigene's marketing partner SynCore, a member of the Sinphar Pharmaceutical Group, is expected in the second half of 2013.

Veregen® is already being marketed in the USA (by Fougera), in Germany, Austria and Switzerland (by Abbott), in Spain (by Bial) as well as in Serbia (by Pharmanova) and approved in further countries. Market approvals and the launch in additional countries are pending in 2013. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy to further leverage the product's market potential.

About Veregen®: Veregen®, an ointment used in the topical treatment of external genital warts, contains a catechin concentrate based on a defined extract obtained from green tea leaves. Since 2010, Veregen® (Sinecatechins 15% ointment) has been recommended in the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines as a possible option for treating genital warts. Sinecatechins 10% & 15% ointment (Veregen®) was recently also included in the European Guideline for the Management of Anogenital Warts.

About SynCore: SynCore Biotechnology Co., Ltd, a joint venture between Sinphar Pharmaceutical Co., Ltd and the National Health Research Institute of Taiwan, is focused on the development of new drugs. Currently, SynCore has five products under development in different stages of clinical trial. Additionally, SynCore has been granted the exclusive development and marketing right in Asia for a new drug for the treatment of dry AMD (age-related macular degeneration) from MacuCLEAR, an US-based biotech company; the drug received approval to enter into phase II/III clinical trial in the US and Taiwan. For further information, please visit

About Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock Exchange, symbol: 1734), with subsidiaries in China and Canada, specializes in the sales and marketing of pharmaceutical products and dietary supplements as well as contract manufacture for several global pharma companies such as Johnson & Johnson, Takeda, Shionogi, and Astellas. Additionally, Sinphar is one of the major producers of paclitaxel (Phyxol®) in Asia. It is also involved in the research and development of botanical new drugs. Further information can be obtained at:

Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to generate revenues from a marketed product (Veregen®), which is distributed by partner companies. Medigene also has two drug candidates undergoing clinical trials, EndoTAG®-1 und RhuDex®, and is developing an innovative vaccine technology. For further details, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please go to